These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 30059594)

  • 21. A forensic perspective of the AFL investigation into peptides: an antidoping investigation case study.
    Harcourt PR; Marclay F; Clothier B
    Br J Sports Med; 2014 May; 48(10):810-3. PubMed ID: 24642697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The list of prohibited substances and methods in sport: structure and review process by the world anti-doping agency.
    Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):608-12. PubMed ID: 22080899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sport-Specific Use of Doping Substances: Analysis of World Anti-Doping Agency Doping Control Tests between 2014 and 2017.
    Aguilar-Navarro M; Salinero JJ; Muñoz-Guerra J; Plata MDM; Del Coso J
    Subst Use Misuse; 2020; 55(8):1361-1369. PubMed ID: 32186429
    [No Abstract]   [Full Text] [Related]  

  • 24. Clean Olympians? Doping and anti-doping: the views of talented young British athletes.
    Bloodworth A; McNamee M
    Int J Drug Policy; 2010 Jul; 21(4):276-82. PubMed ID: 20056401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ensuring high quality in anti-doping laboratories.
    Boghosian T; Barroso O; Ivanova V; Rabin O
    Bioanalysis; 2012 Jul; 4(13):1591-601. PubMed ID: 22831475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief History of Anti-Doping.
    Ljungqvist A
    Med Sport Sci; 2017; 62():1-10. PubMed ID: 28571021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harmonization of anti-doping rules in a global context (World Anti-Doping Agency-laboratory accreditation perspective).
    Ivanova V; Miller JH; Rabin O; Squirrell A; Westwood S
    Bioanalysis; 2012 Jul; 4(13):1603-11. PubMed ID: 22831476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of doping in sports: doping control in Norway, 1977-1995.
    Bahr R; Tjørnhom M
    Clin J Sport Med; 1998 Jan; 8(1):32-7. PubMed ID: 9448955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical experience with the implementation of an athlete's biological profile in athletics, cycling, football and swimming.
    Zorzoli M; Pipe A; Garnier PY; Vouillamoz M; Dvorak J
    Br J Sports Med; 2014 May; 48(10):862-6. PubMed ID: 24648438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance-Enhancing Drugs I: Understanding the Basics of Testing for Banned Substances.
    Cadwallader AB; Murray B
    Int J Sport Nutr Exerc Metab; 2015 Aug; 25(4):396-404. PubMed ID: 25675030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Not Available].
    Bieri A; Kamber M; Sterchi M; Mullis PE
    Ther Umsch; 2014 Apr; 71(4):245-52. PubMed ID: 24670606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Annual banned-substance review: analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H; Schänzer W
    Drug Test Anal; 2011 Jan; 3(1):1-14. PubMed ID: 21254451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analytical progresses of the International Olympic Committee and World Anti-Doping Agency Olympic laboratories.
    Georgakopoulos C; Saugy M; Giraud S; Robinson N; Alsayrafi M
    Bioanalysis; 2012 Jul; 4(13):1549-63. PubMed ID: 22831472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of the health industry in the fight against doping in sport.
    Rabin O
    Forensic Sci Int; 2011 Dec; 213(1-3):10-4. PubMed ID: 21741188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Annual banned-substance review: analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Walpurgis K; Geyer H; Schänzer W
    Drug Test Anal; 2016 Jan; 8(1):7-29. PubMed ID: 26767774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement uncertainty in anti-doping quantitative analysis for prohibited threshold substances.
    Barroso O; Miller J; Squirrell A; Westwood S
    Bioanalysis; 2012 Jul; 4(13):1653-65. PubMed ID: 22831481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Annual banned-substance review: analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H; Schänzer W
    Drug Test Anal; 2010 Apr; 2(4):149-61. PubMed ID: 20376830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Athlete Biological Passport: How to Personalize Anti-Doping Testing across an Athlete's Career?
    Robinson N; Sottas PE; Schumacher YO
    Med Sport Sci; 2017; 62():107-118. PubMed ID: 28578329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Self-reported attitudes of elite athletes towards doping: differences between type of sport.
    Alaranta A; Alaranta H; Holmila J; Palmu P; Pietilä K; Helenius I
    Int J Sports Med; 2006 Oct; 27(10):842-6. PubMed ID: 16586338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.